An Exosomal miRNA-based Liquid Biopsy for ICC Detection
Intrahepatic cholangiocarcinoma (ICC) is a malignant liver tumor with poor prognosis and limited curative treatment options. Early and accurate detection remains an unmet clinical need. The LUMIC study aims to develop a non-invasive liquid biopsy platform based on both exosomal microRNAs (exo-miRNAs) to detect intrahepatic cholangiocarcinoma with high sensitivity and specificity.
Checked against the public recordLast updated Mar 13, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- City of Hope Medical Center
- Interventions being studied
- Diagnostic Test: Small RNA sequencing; Diagnostic Test: LUMIC assay
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Age ≥ 18 years * Histologically confirmed intrahepatic cholangiocarcinoma * Availability of pre-treatment plasma sample * Informed consent provided Exclusion Criteria: * Extrahepatic cholangiocarcinoma * History of other malignancy within 5 years * Active infection, autoimmune disease, or pregnancy * Inadequate clinical data or poor sample quality
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- City of Hope Medical CenterDuarte, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 13, 2026. Always confirm current availability with the study team.